Loading clinical trials...
Loading clinical trials...
Multicentre, Double-blind, Randomised, Parallel Group, Placebo Controlled, Phase 3 Study of the Efficacy & Safety of Quetiapine Fumarate & Paroxetine as Monotherapy in Adult Patients With Bipolar Depression for 8 Weeks & Quetiapine in Continuation (Abbreviated)
The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Research Site
Phoenix, Arizona, United States
Research Site
Little Rock, Arkansas, United States
Research Site
National City, California, United States
Research Site
San Clemente, California, United States
Research Site
San Diego, California, United States
Research Site
Maitland, Florida, United States
Research Site
Winter Park, Florida, United States
Research Site
Atlanta, Georgia, United States
Research Site
Smyrna, Georgia, United States
Research Site
Northfield, Illinois, United States
Start Date
May 1, 2005
Completion Date
May 1, 2007
Last Updated
January 4, 2013
676
ACTUAL participants
quetiapine fumarate (Seroquel)
DRUG
paroxetine
DRUG
mood stabilizing activity
BEHAVIORAL
Lead Sponsor
AstraZeneca
NCT07360600
NCT06793397
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions